ABSTRACT
Understanding the factors that increase the transmissibility of the recently emerging variants of SARS-CoV-2 (such as the Alpha, Epsilon, and Delta variants) can aid in mitigating their spread. The enhanced transmissibility could be attributed to one or more factors: higher stability on surfaces or within droplet nuclei suspended in air, increased maximal viral load or higher probability of infection. The relative importance of these factors on the transmission was examined using a validated stochastic-jump-continuous hybrid model. The transmissibility was quantified in terms of the household secondary attack rate (hSAR) which is the probability of transmission from an infected individual to a susceptible one in a household. We find that an increase in either the maximal viral load or the probability of infection is consistent with the observed hSAR of the variants. Specifically, in order to reach the relative increase in the hSAR of 40%, 55%, and 87% reported for the Epsilon, Alpha, and Delta variants (respectively), the maximal viral load should increase by 56%, 78%, and 125%, respectively. Alternatively, the probability of infection should increase by 34%, 53%, and 193%, respectively. Contrary to these results, even a dramatic increase in environmental stability increases hSAR by no more than 10%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There is no external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not relevant, theoretical research
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data is included in the manuscript